WP 2.16: Peri-operative treatment with tranexamic acid (TXA); prognostic and treatment related impact of the plasmin(ogen) pathway in melanoma

Surgery is a key element in the treatment of melanoma, and naturally linked with an inflammatory response and recruitment of innate immune cells. Although surgery has a favorable intent, surgery-induced inflammation, neutrophils in particular, may accelerating growth of local and systemic micrometastases.

Thus, improving cancer surgery and modulating the microenvironment in ways that benefit the patients is crucial. Our preliminary data from zebrafish studies suggest that the plasminogen pathway is up-regulated in melanoma progression and that this pathway can be inhibited by Tranexamic Acid, subsequently reducing recruitment of neutrophils to a wound. By a randomized clinical trial we are aiming to reduce the early relapses and postoperative complications for the patients, and from peri-operative blood- and tissue samples and collaborative zebrafish experiments, understanding the prognostic and treatment-related impact of the plasminogen pathway in relation to melanoma surgery.

Awarded to: Marie Louise Bønnelykke-Behrndtz (AUH) – CFA2

Awarded grant to support TAP personnel.